Poseida Therapeutics Inc (PSTX)
9.50
0.00 (0.00%)
USD |
NASDAQ |
Jan 08, 16:00
Poseida Therapeutics SG&A Expense (Quarterly): 10.09M for Sept. 30, 2024
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Verastem Inc | 12.28M |
| Galectin Therapeutics Inc | 1.471M |
| Chimerix Inc | 5.173M |
| Revance Therapeutics Inc | 62.22M |
| Sage Therapeutics Inc | 53.22M |